Search

Search results

399 results found

Itching is a significant problem and a mediator between disease severity and quality of life for patients with psoriasis: results from a randomized controlled trial.

Zhu, B, E Edson-Heredia, J Guo, T Maeda-Chubachi, W Shen, and A B Kimball. 2014. “Itching Is a Significant Problem and a Mediator Between Disease Severity and Quality of Life for Patients With Psoriasis: Results from a Randomized Controlled Trial.”. The British Journal of Dermatology 171 (5): 1215-9.

Observations from our evaluation of bodyweight changes after initiation of a biologic therapy in the Psoriasis Longitudinal Assessment and Registry (PSOLAR).

Shear, N H, R Alhusayen, A Fernandez-Obregon, A B Kimball, A Menter, J J Wu, K Goyal, H Patel, R Lin, and A W Armstrong. 2017. “Observations from Our Evaluation of Bodyweight Changes After Initiation of a Biologic Therapy in the Psoriasis Longitudinal Assessment and Registry (PSOLAR).”. Journal of the European Academy of Dermatology and Venereology : JEADV 31 (12): e544-e547.

Apremilast, an oral phosphodiesterase 4 inhibitor, improves patient-reported outcomes in the treatment of moderate to severe psoriasis: results of two phase III randomized, controlled trials.

Thaci, D, A Kimball, P Foley, Y Poulin, E Levi, R Chen, and S R Feldman. 2017. “Apremilast, an Oral Phosphodiesterase 4 Inhibitor, Improves Patient-Reported Outcomes in the Treatment of Moderate to Severe Psoriasis: Results of Two Phase III Randomized, Controlled Trials.”. Journal of the European Academy of Dermatology and Venereology : JEADV 31 (3): 498-506.